CONMED (NYSE: CNMD) to exit gastroenterology lines, end Gore VIABIL stent pact

Rhea-AI Filing Summary

CONMED Corporation reported that it plans to exit its gastroenterology product lines as part of a broader portfolio optimization strategy. The Company announced that this change includes ending its distribution agreement with W.L. Gore & Associates, Inc. for the Gore® VIABIL® biliary stent, effective January 1, 2026, and it expects to exit the rest of its gastroenterology product portfolio as well.

The update was communicated through a press release dated December 5, 2025, which is furnished as an exhibit to this report. The announcement signals a strategic refocus on other parts of CONMED’s business, but the filing does not provide financial details about the gastroenterology products being exited.

Insights

Medical devices strategy analyst

CONMED is exiting gastroenterology products to streamline its portfolio focus.

CONMED is discontinuing its gastroenterology product lines, including ending its distribution agreement for the Gore® VIABIL® biliary stent effective January 1, 2026. This step is described as part of a portfolio optimization strategy, suggesting the company is concentrating resources on other product areas where it sees stronger strategic alignment.

The move removes reliance on a distributed product from W.L. Gore & Associates and simplifies the company’s offering mix. Actual financial impact is not quantified in the disclosure, so the significance depends on how large gastroenterology was within CONMED’s overall revenue. Future company filings and updates after January 1, 2026 may clarify how this exit affects growth mix and margins.

false 0000816956 0000816956 2025-12-05 2025-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 5, 2025

CONMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		001-39218		16-0977505
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

11311 Concept Blvd Largo, FL		33773
(Address of principal executive offices)		(Zip code)

(727) 392-6464

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Rule 12(b) of the Act

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		CNMD		NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 5, 2025, CONMED Corporation (the “Company”) issued a press release announcing its intent to exit its gastroenterology product lines as part of the Company’s portfolio optimization strategy. This includes the termination of its distribution agreement with W.L. Gore & Associates, Inc. for the Gore® VIABIL® biliary stent effective January 1, 2026 and the expected exit from the remaining products in its gastroenterology product portfolio. A copy of this press release is attached hereto as Exhibit 99.1.

The information furnished herewith pursuant to Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1		Press Release, dated December 5, 2025, issued by CONMED Corporation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL Document).

1

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 5, 2025	CONMED CORPORATION
	(Registrant)
	By:	/s/ Todd W. Garner
	Name:	Todd W. Garner
	Title:	Executive Vice President, Finance and Chief Financial Officer

2

FAQ

What strategic change did CONMED (CNMD) announce on December 5, 2025?

On December 5, 2025, CONMED Corporation announced its intent to exit its gastroenterology product lines as part of a portfolio optimization strategy. The company communicated this change through a press release furnished with the report.

Which key distribution agreement is CONMED (CNMD) terminating?

CONMED stated it will terminate its distribution agreement with W.L. Gore & Associates, Inc. for the Gore® VIABIL® biliary stent. The termination is effective January 1, 2026 and is part of the broader exit from its gastroenterology product portfolio.

Does CONMED plan to exit all of its gastroenterology products?

Yes. In addition to ending the Gore® VIABIL® biliary stent distribution agreement, CONMED said it expects to exit the remaining products in its gastroenterology product portfolio as part of this strategic shift.

How did CONMED (CNMD) disclose the exit from gastroenterology product lines?

The company disclosed the change in a press release dated December 5, 2025, which is attached as Exhibit 99.1 to the report. The press release is furnished under an informational item and is not deemed filed for liability purposes under Section 18 of the Exchange Act.

When will the Gore VIABIL biliary stent agreement termination take effect for CONMED?

The termination of CONMED’s distribution agreement with W.L. Gore & Associates, Inc. for the Gore® VIABIL® biliary stent is effective on January 1, 2026, marking a key milestone in the company’s planned exit from gastroenterology products.

Does CONMED (CNMD) provide financial details about the gastroenterology exit in this disclosure?

No specific financial metrics related to the gastroenterology product lines are included in this disclosure. The report focuses on the strategic decision to exit these products and terminate the Gore® VIABIL® biliary stent distribution agreement.